EAACI Congress 2025

Back
13 - 16 June 2025 Glasgow, United Kingdom

Primary and Safety Outcomes of a Phase 3, Open-Label, Single-Arm, 12-Week Study of Treatment with PI3Kδ Inhibitor Leniolisib in Paediatric Patients Aged 4–11 Years With Activated PI3Kδ Syndrome (APDS)

Friday 13 Jun, 12:00 PM - 12:12 PM Glasgow, United Kingdom